Drug Trial Radar · NCT07362264
A Study of SH006 Injection Combination Therapy in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jan 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
50
Planned (sponsor's estimate)
Start
Jul 1, 2025
Primary completion
Dec 30, 2026
Study completion Dec 30, 2028
Sponsor
- Lead sponsor
- Nanjing Sanhome Pharmaceutical, Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 23, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the safety and tolerability of the combination therapy of SH006 injection in patients with advanced solid tumors
Conditions
- Liver Cancer
Interventions
SH006Drug
The dosage of SH006 is 15 mg/kg Q3W or 30 mg/kg Q3W, with a treatment cycle of 21 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1: Number of Participants With Dose Limiting Toxicities (DLTs)Time frame: Days 1-21
- Recommended Phase 2 Dose (RP2D)Time frame: up to 21 days
- Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)Time frame: Within 90 days from the first administration to the last administration of the SH006 combination therapy
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Nanjing Tianyinshan Hospital
Nanjing, Jiangsu, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.